BidaskClub lowered shares of DBV TECHNOLOGIE/S (NASDAQ:DBVT) from a hold rating to a sell rating in a report issued on Friday, BidAskClub reports.

Other analysts also recently issued reports about the stock. Zacks Investment Research raised shares of DBV TECHNOLOGIE/S from a hold rating to a buy rating and set a $9.75 price target for the company in a research note on Wednesday, June 12th. JMP Securities reissued a buy rating and issued a $20.00 price target on shares of DBV TECHNOLOGIE/S in a research note on Wednesday, March 6th. Finally, Stifel Nicolaus reissued a hold rating and issued a $10.00 price target on shares of DBV TECHNOLOGIE/S in a research note on Wednesday, March 6th. Two investment analysts have rated the stock with a sell rating, five have given a hold rating and four have issued a buy rating to the stock. The stock has a consensus rating of Hold and a consensus target price of $14.75.

DBV TECHNOLOGIE/S stock opened at $8.03 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.30 and a current ratio of 3.34. DBV TECHNOLOGIE/S has a twelve month low of $3.60 and a twelve month high of $25.77.

Several large investors have recently modified their holdings of DBVT. Quantamental Technologies LLC raised its stake in shares of DBV TECHNOLOGIE/S by 63.9% during the first quarter. Quantamental Technologies LLC now owns 4,917 shares of the company’s stock valued at $38,000 after acquiring an additional 1,917 shares during the last quarter. Bank of Montreal Can bought a new position in shares of DBV TECHNOLOGIE/S during the first quarter valued at about $113,000. Norges Bank bought a new position in shares of DBV TECHNOLOGIE/S during the fourth quarter valued at about $321,000. OLD Mission Capital LLC raised its stake in shares of DBV TECHNOLOGIE/S by 1,278.6% during the fourth quarter. OLD Mission Capital LLC now owns 143,338 shares of the company’s stock valued at $920,000 after acquiring an additional 132,941 shares during the last quarter. Finally, Premier Asset Management LLC bought a new position in shares of DBV TECHNOLOGIE/S during the fourth quarter valued at about $1,121,000. 46.56% of the stock is owned by hedge funds and other institutional investors.

DBV TECHNOLOGIE/S Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults.

Further Reading: What is a Call Option?

Analyst Recommendations for DBV TECHNOLOGIE/S (NASDAQ:DBVT)

Receive News & Ratings for DBV TECHNOLOGIE/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV TECHNOLOGIE/S and related companies with MarketBeat.com's FREE daily email newsletter.